1. Australia Stocks

  2. •

    Healthcare

  3. •

    Medical - Distribution
EBOS Group Limited

EBOS Group Limited

EBOSY
EBOS Group LimitedUS flagOther OTC
26.00
USD
- -
- -
1.33BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
68.29
78.5
81.09
93.98
100.49
100.18
94.58
116.14
120.8
134.55
139.74
149.98
134.73
Basic EPS, GAAP
1.06
1.26
1.42
1.68
1.75
1.97
1.88
2.15
2.43
2.54
2.89
3.09
2.36
Free Cash Flow per Basic Share
0.87
1.08
1.58
2.82
1.4
-0.83
-0.47
-0.39
-1.08
-1.12
-1.12
-0.96
-0.55
Dividend per Share
0.8
0.71
0.85
1.02
1.25
1.33
1.36
1.48
1.64
1.93
2.01
1.78
1.51
Book Value per Share
11.56
13.75
14.3
14.93
15.37
16
17.13
17.67
18.73
28.73
27.97
28.01
30.33
Tangible Book Value per Share
-21.43
1.69
1.84
1.48
-0.58
-0.02
1.67
2.32
3.2
-2.88
-2.15
-2.04
-0.94
Basic Weighted Avg Shares
27
73
75
76
76
76
77
81
82
88
95
96
98
Sales/Revenue/Turnover
1,822
5,757
6,068
7,101
7,626
7,609
7,251
9,382
9,888
11,902
13,317
14,411
13,209
Operating Margin (%)
7
2.73
2.85
2.88
2.88
3.12
3.29
3.01
3.21
3.32
3.75
3.66
3.45
Depreciation Expense
6
23
24
25
26
35
34
78
78
91
136
141
158
Net Income, GAAP
28
92
106
127
133
150
144
174
199
225
276
297
232
Effective Tax Rate (%)
33.18
26.8
29.69
29.73
29.92
29.41
29.16
29.79
30.02
31.57
29.45
28.72
28.61
Profit Margin (%)
1.55
1.6
1.75
1.79
1.74
1.97
1.99
1.85
2.01
1.89
2.07
2.06
1.75
Working Capital
-504
267
280
246
242
262
290
270
265
613
380
-155
507
LT Debt
155
252
273
261
441
474
381
565
566
1,412
1,296
896
1,658
Total Equity
305
979
1,051
1,087
1,152
1,216
1,297
1,403
1,510
2,386
2,507
2,643
2,933
Return on Invested Capital (%)
16.38
11.05
8.41
9.68
9.53
9.24
9.07
9.56
9.73
8.28
8.62
9
7.12
Return on Capital (%)
6.72
10.88
8.45
9.55
9
9.01
8.84
9.28
9.5
7.47
7.76
8.6
6.55
Return on Common Equity (%)
10.91
13.98
10.19
11.55
11.58
12.56
11.39
12.69
13.45
11.03
10.59
11.08
8.18

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.69%
17.42%
10.99%
Free Cash Flow
-3.84%
29.44%
-41.24%
Net Income, GAAP
8.98%
7.14%
-21.93%
Sales/Revenue/Turnover
8.64%
7.51%
-8.34%
Total Cash Common Dividend
9.61%
5.41%
-13.5%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
13,317
2024
- -
- -
- -
- -
14,411
2025
- -
- -
- -
- -
13,209

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2.89
2024
- -
- -
- -
- -
3.09
2025
- -
- -
- -
- -
2.36

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2.01
2024
- -
- -
- -
- -
1.78
2025
- -
- -
- -
- -
1.51

Company Description

APIChat
CEO
Adam Luke Hall
Full Time Employees
5,200
Sector
Healthcare
Industry
Medical - Distribution
Address
737 Bourke Street Docklands VIC Australia 3008
IPO Date
May 11, 2017
Website
ebosgroup.com
Similar Companies
Alfresa Holdings Corporation (2784.T)
Chandra Bhagat Pharma Limited (CBPL.BO)
Medlive Technology Co., Ltd. (2192.HK)
Charmacy Pharmaceutical Co., Ltd. (2289.HK)
Exlites Holdings International, Inc. (EXHI)
PT Soho Global Health Tbk (SOHO.JK)
Business
EBOS Group Limited (EBOSY), founded in 1922 and headquartered in Docklands, Australia, is the largest diversified marketer, wholesaler and distributor of healthcare, medical, pharmaceutical and animal care products across Australia, New Zealand and Southeast Asia. The company operates through Healthcare and Animal Care segments and offers healthcare logistics; medication management solutions; pharmacy management software including loyalty, generics, compliance, business intelligence and store software services; health communications, programs and consultancy services; community-based healthcare services; vitamins, minerals and supplements; herbal and fruit teas; natural toothpastes; functional foods such as molasses and manuka honey; Pharmacy Choice integrated retail program for independent pharmacies; healthSAVE community pharmacy banner; health and wellness products to public and private hospitals, day surgeries, general practice, aged care facilities, specialist clinics, government and non-profit health agencies; pharmacy services to hospitals, cancer centers, correctional facilities and veterinary clinics; allografts solutions; healthcare distribution, warehousing, clinical trial management and product registration services; clinical trial logistics; aesthetic healthcare devices, medical-grade cosmeceuticals and injectables; surgical devices and medical consumables; pet nutrition, treats, clean-up and grooming products and accessories; and veterinary products for companion animals, production animals and equine athletes. In recent developments, EBOS completed the acquisition of SVS Veterinary Supplies in New Zealand for NZ$115 million upfront plus up to NZ$10 million earn-out in early 2025, establishing a leading position in the New Zealand veterinary wholesale market at approximately 7x EBITDA; acquired the remaining 10% stake in Transmedic for A$35 million; and raised approximately A$200 million via an underwritten placement plus up to A$50 million through a retail offer to fund these transactions and support future growth opportunities. With over 5,200 employees across 115 locations, EBOS serves thousands of customers including hospitals, pharmacies, veterinary clinics and animal care retailers, maintaining its focus on essential healthcare and animal care supply chains.

Company News

APIChat

  • seekingalpha.com

    EBOS Group Limited (EBOSY) Analyst/Investor Day Transcript

  • seekingalpha.com

    EBOS Group Limited (EBOSF) Q2 2026 Earnings Call Transcript